type 1 diabetes

Sanofi paying Lexicon $260M to exit diabetes alliance
Sanofi paying Lexicon $260M to exit diabetes alliance
BioPharma Dive
Sanofi
Lexicon Pharmaceuticals
diabetes
type 1 diabetes
Zynquista
Flag link:
Vertex’s next act: a billion-dollar bet on a cure for type 1 diabetes
Vertex’s next act: a billion-dollar bet on a cure for type 1 diabetes
Stat
Vertex Pharmaceuticals
M&A
diabetes
type 1 diabetes
Semma Therapeutics
Flag link:
How one Boston startup rode the diabetes investment wave to raise $126M
How one Boston startup rode the diabetes investment wave to raise $126M
Bizjournals
Beta Bionics
type 1 diabetes
startups
devices
Flag link:
Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
Yahoo/Reuters
Sanofi
Lexicon Pharmaceuticals
type 1 diabetes
type 2 diabetes
diabetes
insulin
Flag link:
AstraZeneca's Farxiga fails to get U.S. approval for Type-1 diabetes
AstraZeneca's Farxiga fails to get U.S. approval for Type-1 diabetes
Yahoo/Reuters
AstraZeneca
FDA
Farxiga
type 1 diabetes
Flag link:
Can A Drug That Delays The Onset Of Type 1 Diabetes Be A Success?
Can A Drug That Delays The Onset Of Type 1 Diabetes Be A Success?
Forbes
type 1 diabetes
Eli Lilly
teplizumab
Flag link:
Provention’s Teplizumab Can Delay Onset of Type 1 Diabetes, Trial Results Show
Provention’s Teplizumab Can Delay Onset of Type 1 Diabetes, Trial Results Show
BioSpace
Povention Bio
clinical trials
type 1 diabetes
ADA
immunotherapy
Flag link:
A lifesaver with a catch: Powerful new cancer drugs can trigger diabetes — and no one is certain why
A lifesaver with a catch: Powerful new cancer drugs can trigger diabetes — and no one is certain why
Stat
type 1 diabetes
checkpoint inhibitors
cancer
Flag link:
Harvard-born diabetes startup Semma reports advances in turning stem cells into insulin producers
Harvard-born diabetes startup Semma reports advances in turning stem cells into insulin producers
Fierce Biotech
Semma Therapeutics
type 1 diabetes
Flag link:
Sanofi, Lexicon get complete response letter for Zynquista
Sanofi, Lexicon get complete response letter for Zynquista
BioCentury
Sanofi
Zynquista
Lexicon Pharmaceuticals
type 1 diabetes
FDA
Flag link:
AI Used to ID Risk of Heart Disease in Diabetes Study
AI Used to ID Risk of Heart Disease in Diabetes Study
Medical Devices and Diagnostics Industry
type 1 diabetes
artificial intelligence
heart disease
diagnostics
Flag link:
AbbVie’s cancer drug Venclexta blocks diabetes in mice by targeting beta cell ‘senescence’
AbbVie’s cancer drug Venclexta blocks diabetes in mice by targeting beta cell ‘senescence’
Fierce Biotech
senescence
Venclexta
type 1 diabetes
AbbVie
Flag link:
JDRF Disappointed by UnitedHealthcare’s Preferred Medtronic Insulin Pump
JDRF Disappointed by UnitedHealthcare’s Preferred Medtronic Insulin Pump
Xtalks
type 1 diabetes
JDRF
Medtronic
devices
MiniMed 670G
UnitedHealthcare
Flag link:
AstraZeneca’s Forxiga recommended for marketing authorization in EU
AstraZeneca’s Forxiga recommended for marketing authorization in EU
Pharmaceutical Business Review
EMA
AstraZeneca
Forxiga
type 1 diabetes
CHMP
Flag link:
U.S. insulin costs per patient nearly doubled from 2012 to 2016: study
U.S. insulin costs per patient nearly doubled from 2012 to 2016: study
Reuters
insulin
drug pricing
type 1 diabetes
Flag link:
FDA advisers divided on Sanofi’s oral type 1 diabetes drug
FDA advisers divided on Sanofi’s oral type 1 diabetes drug
Pharmaforum
Sanofi
Lexicon Pharmaceuticals
type 1 diabetes
Zynquista
FDA
advisory panels
sotagliflozin
Flag link:
Daiichi Sankyo takes option on diabetes stem cell start-up
Daiichi Sankyo takes option on diabetes stem cell start-up
Pharmaforum
Daiichi Sankyo
stem cells
Tokyo Institute of Technology
type 1 diabetes
OiDE BetaRevive
Flag link:
A vaccine for Type 1 diabetes? Provention Bio says a human trial is in sight
A vaccine for Type 1 diabetes? Provention Bio says a human trial is in sight
Fierce Biotech
type 1 diabetes
Provention Bio
vaccines
PRV-101
Flag link:
Eli Lilly's diabetes treatment meets main goal in two late-stage studies
Eli Lilly's diabetes treatment meets main goal in two late-stage studies
Reuters
Eli Lilly
Ultra Rapid Lispro
Humalog
diabetes
type 1 diabetes
type 2 diabetes
Flag link:
New Therapy Could Reverse Type 1 Diabetes In Humans And Dogs
New Therapy Could Reverse Type 1 Diabetes In Humans And Dogs
Forbes
type 1 diabetes
animal health
diabetes
collagen
Flag link:

Pages